胰激肽原酶对糖尿病神经原性膀胱的疗效观察

目的探讨胰激肽原酶（PK）对糖尿病神经原性膀胱的疗效。方法40例糖尿病神经原性膀胱女性患者随机分为PK治疗组（PK组）、对照组（Con组）各20例。PK组日1次肌注PK40U；Con组日1次肌注维生素B12 500μg。治疗前及治疗后的1个月、2个月检测尿流率、残余尿、最大尿流率、平均尿流率及排尿期逼尿肌压。结果治疗后PK组残余尿量显著降低，最大尿流率、平均尿流率及排尿期逼尿肌压均显著增加（P〈0.05）。Con组治疗后1个月各项结果较治疗前无统计学差异（P〉0.05）。治疗后2个月残余尿量轻度降低，最大尿流率及排尿期逼尿肌压升高，较治疗前差异有统计学意义（P〈0．05）。PK组与Con组比较，残余尿量更低，最大尿流率、平均尿流率及排尿期逼尿肌压更高，差异有统计学意义（P〈0.05）。结论胰激肽原酶可以作为治疗糖尿病神经原性膀胱的用药之一。

Observations of therapeutic effect of pancreatic kininogenase treatment on diabetic neurogenic bladder

Objective To investigate the therapeutic effect of pancreatic kininogenase（PK）on diabetic neurogenic bladder. Methods Forty female patients were randomly divided into 2 groups： PK（group A, n = 20） and control （group B,vitamin B12, n= 20）. The residual urine, uroflowmetry and the detrusor pressure in voiding period examination were done before the therapy,and one month and two months after the therapy. Results After the treatment, group A showed that the volume of residual urine was decreased markably, the maximum and the average urinary flow rates and the detrusor pressure in voiding period were increased notably （P〈0. 05）. Compared with group B, the residual urine of group A was significantly lower, the maximum and the average urinary flow rates and the detrusor pressure in voiding period were significantly higher（P〈0.05）. Conclusions PK can be utilized to treat the diabetic neurogenic bladder.